The First Experience of Application the Umbilical Cord-Derived Human Autologous Mesenchymal Stromal Cells for the Rehabilitation Therapy of Premature Infants with Extremely Low Body Weight and Hypoxic-Ischemic Encephalopathy

Devyaltovskaya, M. G.; Nikitchanko, D. Yu.; Потапнев, М. П.; Petyovka, N. V.; Kastsiunina, V. S.

doi:10.1007/s10517-022-05663-4

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesenchymal stem cells (MSCs) have potent anti-inflammatory and antiapoptotic properties, especially the pleiotropic neuroprotection of MSCs, [ 62 , 63 ] an experimental animal study found [ 64 ] that injection of human embryonic stem cell-derived MSCs into a mouse model resulted in some improvement in neurobehavior of the treated mice. Devyaltovskaya et al [ 65 ] reported 2 clinical cases of application of umbilical cord-derived somatic MSCs for the treatment of hypoxic-ischemic encephalopathy rehabilitation in very preterm infants (27–28 weeks of gestation, weighing 900 and 870 g, respectively), in which children were sampled at birth with umbilical cord-derived MSCs, and the cells were injected at doses of 1.6 to 7 million per kilogram (MW/kg) at the ages of 3, 6, 12 months (the first patient) and 3, 6, 9, 15 months (the second patient). 7 million/kg of cells were injected.…”

Section: Medicationmentioning

confidence: 99%

Current status and controversies in the treatment of neonatal hypoxic-ischemic encephalopathy: A review

Gao,

Jiang

2024

Medicine

View full text Add to dashboard Cite

Neonatal hypoxic-ischemic encephalopathy is a type of traumatic brain injury caused by insufficient cerebral perfusion and oxygen supply in the perinatal neonate, which can be accompanied by different types of long-term neurodevelopmental sequelae, such as cerebral palsy, learning disabilities, mental retardation and epilepsy It is one of the main causes of neonatal death and disability, and it has caused a great burden on families and society. Therefore, this article mainly reviews the latest developments in mild hypothermia therapy and related drugs for neonatal hypoxic-ischemic encephalopathy.

show abstract

Section: Medicationmentioning

confidence: 99%

Current status and controversies in the treatment of neonatal hypoxic-ischemic encephalopathy: A review

Gao,

Jiang

2024

Medicine

View full text Add to dashboard Cite

show abstract

“… 1 – 14 Clinically, MSCs show excellent patient safety profiles and apparently positive patient outcomes. 15 The major issue at present is lack of definitive evidence for efficacy from randomized controlled trials. Importantly, MSCs can be readily obtained from a range of sources and the field has seen significant commercialization, with many off-the-shelf MSC products developed to offer long-term scalable solutions.…”

Section: Msc Therapiesmentioning

confidence: 99%

Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022)

et al. 2023

View full text Add to dashboard Cite

Despite considerable advances, there is a need to improve the outcomes of newborn infants, especially related to prematurity, encephalopathy and other conditions. In principle, cell therapies have the potential to protect, repair, or sometimes regenerate vital tissues; and improve or sustain organ function. In this review, we present highlights from the First Neonatal Cell Therapies Symposium (2022). Cells tested in preclinical and clinical studies include mesenchymal stromal cells from various sources, umbilical cord blood and cord tissue derived cells, and placental tissue and membrane derived cells. Overall, most preclinical studies suggest potential for benefit, but many of the cells tested were not adequately defined, and the optimal cell type, timing, frequency, cell dose or the most effective protocols for the targeted conditions is not known. There is as yet no clinical evidence for benefit, but several early phase clinical trials are now assessing safety in newborn babies. We discuss parental perspectives on their involvement in these trials, and lessons learnt from previous translational work of promising neonatal therapies. Finally, we make a call to the many research groups around the world working in this exciting yet complex field, to work together to make substantial and timely progress to address the knowledge gaps and move the field forward. Impact Survival of preterm and sick newborn infants is improving, but they continue to be at high risk of many systemic and organ-specific complications. Cell therapies show promising results in preclinical models of various neonatal conditions and early phase clinical trials have been completed or underway. Progress on the potential utility of cell therapies for neonatal conditions, parental perspectives and translational aspects are discussed in this paper.

show abstract

The First Experience of Application the Umbilical Cord-Derived Human Autologous Mesenchymal Stromal Cells for the Rehabilitation Therapy of Premature Infants with Extremely Low Body Weight and Hypoxic-Ischemic Encephalopathy

Cited by 2 publications

References 16 publications

Current status and controversies in the treatment of neonatal hypoxic-ischemic encephalopathy: A review

Current status and controversies in the treatment of neonatal hypoxic-ischemic encephalopathy: A review

Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022)

Contact Info

Product

Resources

About